FBXL14 abolishes breast cancer progression by targeting CDCP1 for proteasomal degradation

Area of Science:

• Oncology
• Molecular Biology
• Biochemistry

Background:

• CUB-domain-containing protein 1 (CDCP1) is crucial for metastasis in triple-negative breast cancer (TNBC).
• CDCP1 gene expression is a proposed prognostic marker, but protein levels are more relevant and affected by post-transcriptional regulation.
• Understanding CDCP1 regulation is key for developing new breast cancer therapies.

Purpose of the Study:

• To elucidate the post-transcriptional regulatory mechanisms controlling CDCP1 protein stability.
• To identify upstream regulators of CDCP1 relevant to breast cancer progression and prognosis.
• To establish a more reliable prognostic marker for breast cancer patients.

Main Methods:

• Investigated the role of microRNA-17/20a in regulating CDCP1.
• Identified FBXL14 as an E3 ligase controlling CDCP1 ubiquitination and degradation.
• Examined the interaction between FBXL14 and CDCP1.
• Assessed the impact of FBXL14 on CDCP1 protein stability and downstream targets.

Main Results:

• miR-17/20a directly controls the E3 ligase FBXL14.
• FBXL14 interacts with CDCP1, promoting its ubiquitination and proteasomal degradation.
• FBXL14 suppresses CDCP1 protein stability, inhibiting metastasis-associated genes.
• This pathway provides a novel mechanism for CDCP1 protein regulation.

Conclusions:

• FBXL14 is an upstream regulator of the CDCP1 pathway, controlling its protein stability.
• CDCP1 protein levels, regulated by FBXL14, offer a more predictable prognostic criterion than gene expression for breast cancer.
• This discovery opens avenues for targeted therapies by modulating the FBXL14-CDCP1 axis.